Tobias Kampfenkel, Chief Medical Officer (CMO) of Early Clinical Development & Translational Research at Miltenyi Biomedicine, shared on LinkedIn:
“Great to be in Beijing for the 2026 CSGCT Annual Meeting.
I had the opportunity to present Milteny’s journey from oncology CAR-T foundations to immune reset in autoimmune disease, sharing our experience with our investigational CD19 CAR-T zorpo-cel.
I also shared Miltenyi’s proprietary in-vivo CAR-T platform, with design principles including highly selective immune-cell targeting and mitigation of early immune activation.
A great scientific exchange and a special thank you to my Miltenyi colleagues in China for their wonderful hospitality.”
You may also be interested in: Yan Leyfman: What If Resistance to CAR-T Therapy Begins Before Treatment Even Starts?
